STAT

Opinion: Liquid biopsy research should include the perspectives of patients like me

I'm a rational, level-headed patient advocate. But I lost it when facing a biopsy for my own #cancer diagnosis. A #liquidbiopsy would have helped.

Eleven years ago, I was shocked to be diagnosed with advanced lymphoma. To offer an informed second opinion, an oncologist recommended that I have a standard-of-care CT-guided thoracic biopsy. The goal was to collect a tissue sample from one of the nodules on my lung or from the mass in the middle of my chest that an earlier PET scan had detected.

I hope I never have to undergo a biopsy like that again. It’s why I’m incredibly excited at the prospect of what are being called liquid biopsies. These are essentially blood tests used to collect a sample of cancer cells or pieces of DNA from them.

The option to

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks